Public register entity · Japan
大正製薬ホールディングス株式会社
E25678.JP
- Basis
- consolidated
- Source
- FSA EDINET ↗
Financial data filed with a public register. Not a listed company and not a tradable security — this page carries no price and no forecast.
Public register entity · Japan
E25678.JP
Financial data filed with a public register. Not a listed company and not a tradable security — this page carries no price and no forecast.
As first reported — the figures as originally filed, not later restatements.
Latest filing: FY2023 · 2023-03-31Filed 2023-06-29
| Metric | Value |
|---|---|
| Revenue | 301.4B |
| Net income | 19B |
| Total assets | 941.5B |
| Total equity | 809.3B |
| Cash | 232.1B |
| EPS (diluted) | 231.43 |
| Net margin | 6.3% |
| Return on equity | 2.3% |
| Return on assets | 2.0% |
Free, no sign-up — built from official regulator filings.
出典：EDINET閲覧（提出）サイト（https://disclosure2.edinet-fsa.go.jp/）、公共データ利用規約（第1.0版）PDL1.0（https://disclosure2dl.edinet-fsa.go.jp/guide/static/disclosure/WZEK0030.html） — Source: Financial Services Agency (Japan), EDINET, under Public Data License 1.0